China Shineway Pharmaceutical Group Limited

Healthcare US CSWYF

1.004USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

Day Range

1.001.00

LowHigh

52 Week Range

0.911.00

LowHigh

Fundamentals

Previous Close 1.00
Market Cap815.83M
Volume0
P/E Ratio5.14
Dividend Yield46.81%
EBITDA737.52M
Revenue TTM3135.42M
Revenue Per Share TTM4.15
Gross Profit TTM 2266.21M
Diluted EPS TTM0.21

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Income before tax	1145.72M	175.46M	917.02M	720.10M	395.02M
Minority interest	-	-	-	-	-
Net income	840.05M	137.16M	722.77M	556.67M	295.03M
Selling general administrative	291.32M	326.50M	2098.46M	1756.24M	1458.83M
Selling and marketing expenses	1597.31M	1981.62M	-	-	-
Gross profit	2831.75M	3394.12M	2938.31M	2410.34M	1987.85M
Reconciled depreciation	68.73M	177.10M	185.86M	182.39M	208.41M
Ebit	1151.85M	1242.99M	713.58M	534.37M	422.40M
Ebitda	1220.59M	1251.51M	1103.52M	721.36M	620.04M
Depreciation and amortization	68.73M	8.52M	-	-	-
Non operating income net other	-	-	-	-	-
Operating income	842.60M	975.53M	722.40M	541.39M	429.31M
Other operating expenses	2935.44M	3541.00M	-	-	-
Interest expense	6.13M	2.74M	0.63M	1.25M	16.60M
Tax provision	305.67M	270.74M	194.25M	163.43M	99.99M
Interest income	176.72M	95.21M	92.43M	95.07M	87.83M
Net interest income	170.59M	92.47M	91.80M	93.81M	71.23M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	305.67M	38.30M	194.25M	163.43M	99.99M
Total revenue	3778.04M	4516.54M	3950.64M	3223.55M	2655.70M
Total operating expenses	1989.15M	2418.58M	3228.23M	2682.16M	2226.39M
Cost of revenue	946.29M	1122.42M	1012.32M	813.21M	667.86M
Total other income expense net	303.12M	-800.07282M	-	-	-
Discontinued operations	-	-	-	-	-
Net income from continuing ops	840.05M	969.51M	722.77M	556.67M	295.03M
Net income applicable to common shares	-	-	722.77M	556.67M	295.03M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total assets	10041.53M	1349.57M	8231.86M	7203.96M	7213.51M
Intangible assets	23.32M	32.79M	47.35M	66.43M	36.96M
Earning assets	-	-	-	-	-
Other current assets	93.28M	1348.24M	32.01M	35.06M	343.99M
Total liab	2574.63M	357.93M	1849.34M	1302.48M	1419.33M
Total stockholder equity	7466.90M	991.63M	6382.53M	5901.48M	5794.18M
Deferred long term liab	-	-	-	-	-
Other current liab	1624.49M	1633.03M	493.55M	378.95M	334.08M
Common stock	87.66M	12.36M	87.66M	87.66M	87.66M
Capital stock	87.66M	87.66M	87.66M	87.66M	87.66M
Retained earnings	6726.44M	6326.28M	6367.61M	5879.00M	5777.80M
Other liab	-	-	182.83M	196.78M	209.61M
Good will	165.96M	165.96M	165.96M	165.96M	102.50M
Other assets	-	-8224.42655M	19.22M	20.46M	160.24M
Cash	6140.15M	5888.78M	5026.27M	4205.72M	3943.01M
Cash and equivalents	-	-	-	-	-
Total current liabilities	2450.00M	2433.72M	1665.59M	1098.37M	1194.69M
Current deferred revenue	-	17.96M	-	-	-
Net debt	-5793.62600M	-5587.45000M	-	-	-
Short term debt	338.27M	300.97M	-	-	-
Short long term debt	330.00M	300.00M	-	0.00000M	369.32M
Short long term debt total	346.53M	301.33M	-	-	-
Other stockholder equity	652.81M	-5277.28148M	-494.89100M	-487.32000M	-493.41700M
Property plant equipment	-	-	1216.94M	1252.00M	1394.77M
Total current assets	8598.52M	8154.73M	6782.40M	5699.11M	5519.04M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	6169.22M	5669.10M	5654.73M
Short term investments	350.02M	20.00M	20.23M	-	-
Net receivables	1201.88M	1324.96M	1042.54M	866.05M	783.73M
Long term debt	-	-	-	-	-
Inventory	813.19M	897.71M	657.66M	587.96M	443.00M
Accounts payable	402.96M	484.79M	308.75M	228.62M	164.38M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-69.72456M	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	4.62M	-	-	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	1443.01M	1419.26M	1449.46M	1504.85M	1694.47M
Capital lease obligations	16.53M	1.33M	7.44M	14.91M	22.82M
Long term debt total	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Investments	-272.11000M	-49.54000M	6.67M	8.74M	43.91M
Change to liabilities	-	-	147.36M	73.60M	-4.66700M
Total cashflows from investing activities	-272.11000M	-16.05208M	-45.42000M	395.01M	-305.59100M
Net borrowings	30.00M	300.00M	-7.68000M	-378.03300M	-34.88500M
Total cash from financing activities	-392.47500M	-26.73800M	-250.03800M	-828.93500M	-329.78800M
Change to operating activities	-	-	370.99M	176.71M	148.20M
Net income	1145.72M	137.16M	722.77M	556.67M	295.03M
Change in cash	251.38M	104.80M	820.54M	262.71M	-2.99600M
Begin period cash flow	5888.78M	728.76M	4205.72M	3943.01M	3946.01M
End period cash flow	6140.15M	830.09M	5026.27M	4205.72M	3943.01M
Total cash from operating activities	963.13M	140.62M	1109.68M	703.15M	638.57M
Issuance of capital stock	-	-	0.00000M	3.66M	36.44M
Depreciation	68.73M	8.52M	185.86M	182.39M	208.41M
Other cashflows from investing activities	184.40M	2.88M	73.88M	388.92M	-172.53400M
Dividends paid	407.92M	44.70M	-241.72800M	-453.07200M	-173.55800M
Change to inventory	169.97M	-33.96057M	-69.70300M	-140.13200M	-12.19600M
Change to account receivables	51.76M	-41.13254M	-158.70700M	-66.96600M	-93.26400M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-14.55900M	-24.48038M	-0.63000M	-1.49300M	-16.99400M
Change to netincome	-	-	-88.90100M	-79.12000M	97.05M
Capital expenditures	140.11M	20.33M	129.46M	93.63M	66.03M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	221.96M	-23.68396M	289.94M	43.21M	38.07M
Stock based compensation	-	-	0.00000M	0.03M	0.13M
Other non cash items	-473.28000M	18.62M	-122.20700M	-118.94500M	-79.72600M
Free cash flow	823.02M	120.20M	980.21M	609.52M	572.54M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
CSWYF China Shineway Pharmaceutical Group Limited	- -%	1.00	5.14	11.60	0.26	0.78	0.03	0.09
ZTS Zoetis Inc	-2.82 3.58%	75.89	40.18	30.96	10.67	17.60	11.27	26.18
MKKGY Merck KGaA ADR	-0.19 0.62%	30.56	21.25	14.93	3.10	2.14	3.60	12.98
MKGAF MERCK Kommanditgesellschaft auf Aktien	- -%	157.12	21.73	14.95	3.16	2.15	3.56	12.82
GALDY GALDERMA GROUP AG	- -%	42.94	74.21	41.67	8.64	5.55	9.15	42.22

Reports Covered

View All

Profile

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.

China Shineway Pharmaceutical Group Limited

No. 168, Shiluan Street, Shijiazhuang, China, 051430

86 31 1880 30066
https://www.shineway.com
Employees : 2867

Key Executives

Name	Title	Year Born
Mr. Zhenjiang Li	Co-Founder & Exec. Chairman	1955
Ms. Yunxia Xin	Co-Founder & Exec. Director	1963
Mr. Huimin Li	Exec. Director	1968
Mr. Bun Ching Lee	Financial Controller & Company Sec.	1973
Mr. King Kuen Hung	Director of Investor Relation	1966
Mr. Yudong Zhang	Gen. Mang. of Sales & Marketing	1974
Mr. Tiejun Liu	Exec. Director	1974
Mr. Zhenjiang Li	Co-Founder & Executive Chairman	1955
Ms. Yunxia Xin	Co-Founder & Executive Director	1963
Mr. Huimin Li	Executive Director	1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.